Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-1313
Gout Therapeutic Market is estimated to value over CAGR of over 8% during the forecast period 2022 to 2028 Growing adoption of biologics such as Rilonacept, Canakinumab and Krystexxa have been launched in the market and the expansion in the adoption of these biologics, owing to their ability to create strong anti-inflammatory action is registered to boost the market value during the forecast time frame. In addition, a number of other drugs that are undergoing clinical trials are projected to augment the gout therapeutic market growth. Research analysis has shown that the volume of gout has showcased significant growth in recent years. It is primarily attributed to untreated or uncontrolled metabolic disorder and exceedingly high levels of uric acid present in the body. North America is registered to have a heightened gout market due to lifestyle-related problems such as obesity, high intake of alcohol and even inflammatory illnesses. Measures have been undertaken by various nations to raise awareness regarding chronic diseases and how biologics has contributed to the treatment of gout in the populations. In fact, the acceptance of new treatments and a better awareness regarding arthritic and chronic conditions, will most likely propel the market growth. Recommendations of various medications and therapies are given to the patients and the medications are prescribed according to the severity of the ailment. Numerous companies have boosted their investments in research and development to give way for new and improved innovations in medication. Based on the segmentation of components, the drug type in the market for gout therapeutics has been categorized into biologics, colchicine, NSAIDS, antihyperuricemic agents (also known as urate-lowering drugs) and corticosteroids. Biologics has seen a rise in adoption and are an alternative to corticosteroids and NSAIDS, as they culminate in far more effective results. It is for this reason that the biologics segment is expected to grow and in all likelihood, gain sizable gout therapeutic market share during the forecast time frame. Antihyperuricemic agents which are also known as urate-lowering drugs, are usually recommended as the first phase of treatment. Furthermore, the acceptance and subsequent success Target 2 Treat, entails integrating both biologic as well as synthetic urate-lowering drugs. Extensive usage of these drugs in treating gout disease have contributed to the market shares in antihyperuricemic agents and biologic segments. In terms of the distribution channel, the market for gout therapeutics has been fragmented into online, retail and hospital pharmacies. In recent years, the segment for retail pharmacy has witnessed large shares in the market on a scale. Major players who are controlling this market includes Teijin Pharma Limited, Horizon Pharma plc, Novartis AG, Merck & Co. Inc., Ironwood Pharmaceuticals, Inc., Grunenthal Group, JW Pharmaceutical, Takeda Pharmaceutical Company Limited, Selecta Biosciences, Inc., AstraZeneca, Regeneron Pharmaceuticals, Inc. Gout Therapeutic Market Segmentation: By Disease Condition Acute Gout Chronic Gout By Drug Class Colchicine Antihyperuricemic agents (Urate-Lowering Drugs) Non-steroidal Anti-inflammatory Drugs (NSAIDs) Corticosteroids Biologic Response Modifiers (Biologics) By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy By Region Europe North America Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the market by disease condition, by drug class, by distribution channel, and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Growing adoption of biologics such as Rilonacept, Canakinumab and Krystexxa have been launched in the market and the expansion in the adoption of these biologics, owing to their ability to create strong anti-inflammatory action is registered to boost the market value during the forecast time frame. In addition, a number of other drugs that are undergoing clinical trials are projected to augment the gout therapeutic market growth.
Research analysis has shown that the volume of gout has showcased significant growth in recent years. It is primarily attributed to untreated or uncontrolled metabolic disorder and exceedingly high levels of uric acid present in the body. North America is registered to have a heightened gout market due to lifestyle-related problems such as obesity, high intake of alcohol and even inflammatory illnesses. Measures have been undertaken by various nations to raise awareness regarding chronic diseases and how biologics has contributed to the treatment of gout in the populations. In fact, the acceptance of new treatments and a better awareness regarding arthritic and chronic conditions, will most likely propel the market growth.
Recommendations of various medications and therapies are given to the patients and the medications are prescribed according to the severity of the ailment. Numerous companies have boosted their investments in research and development to give way for new and improved innovations in medication.
Based on the segmentation of components, the drug type in the market for gout therapeutics has been categorized into biologics, colchicine, NSAIDS, antihyperuricemic agents (also known as urate-lowering drugs) and corticosteroids. Biologics has seen a rise in adoption and are an alternative to corticosteroids and NSAIDS, as they culminate in far more effective results. It is for this reason that the biologics segment is expected to grow and in all likelihood, gain sizable gout therapeutic market share during the forecast time frame.
Antihyperuricemic agents which are also known as urate-lowering drugs, are usually recommended as the first phase of treatment. Furthermore, the acceptance and subsequent success Target 2 Treat, entails integrating both biologic as well as synthetic urate-lowering drugs. Extensive usage of these drugs in treating gout disease have contributed to the market shares in antihyperuricemic agents and biologic segments.
In terms of the distribution channel, the market for gout therapeutics has been fragmented into online, retail and hospital pharmacies. In recent years, the segment for retail pharmacy has witnessed large shares in the market on a scale.
Major players who are controlling this market includes Teijin Pharma Limited, Horizon Pharma plc, Novartis AG, Merck & Co. Inc., Ironwood Pharmaceuticals, Inc., Grunenthal Group, JW Pharmaceutical, Takeda Pharmaceutical Company Limited, Selecta Biosciences, Inc., AstraZeneca, Regeneron Pharmaceuticals, Inc.
Gout Therapeutic Market Segmentation:
By Disease Condition
By Drug Class
By Distribution Channel
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Gout Therapeutic Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Gout Therapeutic Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Gout Therapeutic Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Gout Therapeutic Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Gout Therapeutic Market, By Disease Condition Historical Analysis and Forecast 2022-2028 (USD Million) 7.1 Acute Gout 7.2 Chronic Gout 8. Global Gout Therapeutic Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Colchicine 8.2. Antihyperuricemic agents (Urate-Lowering Drugs) 8.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs) 8.4. Corticosteroids 8.5. Biologic Response Modifiers (Biologics) 9. Global Gout Therapeutic Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Switzerland 12.2.9. Rest of Western Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. Singapore 13.2.4. India 13.2.5. Australia and New Zealand 13.2.6. ASEAN 13.2.7. South Korea 13.2.8. Taiwan 13.2.9. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. Teijin Pharma Limited 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Horizon Pharma plc 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Novartis AG 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Merck & Co. Inc. 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Ironwood Pharmaceuticals, Inc. 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Grunenthal Group 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. JW Pharmaceutical 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Takeda Pharmaceutical Company Limited 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Selecta Biosciences, Inc. 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. AstraZeneca 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11. Regeneron Pharmaceuticals, Inc 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics